# Enso Ventures

> Enso Ventures is a VC fund in London backing Biotechnology and Therapeutics. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 8
- Last investment: Oct 2017
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1273788
- X (Twitter): https://twitter.com/ensoventures
- Website: http://www.ensoventures.com
- Facebook: https://www.facebook.com/Enso-Ventures-824164324335225/?fref=ts

Enso Ventures is a private investment and project management company that specializes in making selective equity investments in high-technology and bio-tech companies

## Contacts

5 contacts available for Enso Ventures. Shizune tracks 1 team members at Enso Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ensoventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.6M–$14M |
| Series B | $5M–$14M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 75% |
| Therapeutics | 4 | 50% |
| Biopharma | 3 | 38% |
| Health Care | 3 | 38% |
| Life Science | 2 | 25% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 50% |
| Series B | 4 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 75% |
| United Kingdom | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Nikolay Danilov | Managing Director | 0 | https://shizune.co/investors/profile/nikolay-danilov |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cognitive Geology | Founded in 2014, Cognitive Geology operates as a specialist software provider for the oil industry. | $2.6M | Series A | Oct 06, 2017 |  |
| NeuroVia | NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD. | $14M | Series A | Jul 20, 2017 |  |
| Cavion | Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3).Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, theywere the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers.Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. |  | Series A | Jan 06, 2017 |  |
| Galera Therapeutics | Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $5M | Series B | Feb 03, 2016 |  |
| Seres Therapeutics | Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbioticmicrobiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. | $10M | Series B | May 23, 2014 |  |
| Axcella | Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates inmuscle, neurodegenerative, and liver conditions. |  | Series B | Dec 11, 2013 |  |
| Seres Therapeutics | Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbioticmicrobiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. | $10.5M | Series A | Nov 21, 2013 |  |
| Egalet | Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and hasoptimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids. | $14.3M | Series B | May 07, 2012 |  |

8 of 8 investments shown.

## Co-investors
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 3 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 3 deals together
- [Alexandria](https://shizune.co/investors/profile/alexandria-venture) — VC Fund, 1 deal together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [BioMed Ventures](https://shizune.co/investors/profile/biomed-ventures) — VC Fund, 1 deal together
- [Correlation Ventures](https://shizune.co/investors/profile/correlation-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Chevron Technology Ventures](https://shizune.co/investors/profile/chevron-technology-ventures) — VC Fund
- [Evok Innovations](https://shizune.co/investors/profile/evok-innovations) — VC Fund
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Oil and Gas Investors in United Kingdom](https://shizune.co/investors/oil-and-gas-investors-united-kingdom)
- [Oil and Gas VC Funds in United Kingdom](https://shizune.co/investors/oil-and-gas-vc-funds-united-kingdom)
- [Oil and Gas VC Funds in Europe](https://shizune.co/investors/oil-and-gas-vc-funds-europe)

## FAQ

### What does Enso Ventures invest in?

Enso Ventures invests primarily in Biotechnology, Therapeutics and Biopharma startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Enso Ventures's check size?

Enso Ventures typically joins rounds of $2.6M–$14M at Series A and $5M–$14M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Enso Ventures participates in.

### How do I contact Enso Ventures?

Public channels for Enso Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Enso Ventures?

The team at Enso Ventures includes Nikolay Danilov (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co